Turnstone Biologics Corp.
Turnstone Biologics Corp. (TSBX): 3 pipeline candidates · ~14 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
13.5 months
D/E 0.43 · 0% dilution
Lead: Phase 1
3 candidates
N/A
N/A
A transparent, data-derived signal for Turnstone Biologics Corp.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$18.6M
Quarterly Burn
$4.3M
Runway
13.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| hcb301 | Phase 1 |
| not specified | — |
| tbio-6517 | Phase 1 |
Frequently asked questions
How many drug candidates are in Turnstone Biologics Corp.'s pipeline?
Turnstone Biologics Corp. (TSBX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Turnstone Biologics Corp.'s lead drug candidate?
Turnstone Biologics Corp.'s most advanced tracked candidate is hcb301 (Phase 1) for Advanced Solid Tumor.
What is Turnstone Biologics Corp.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Turnstone Biologics Corp. has approximately 13.5 months of cash runway.
Who is the CEO of Turnstone Biologics Corp.?
Fulcrum Therapeutics is the chief executive officer of Turnstone Biologics Corp. (TSBX).
Get the full picture on Turnstone Biologics Corp.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.